Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HRTX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bupivacaine And Meloxicam FDA approved May 2021 · Zynrelef Kit |
Post Operative Pain, Acute | Phase 4 · NCT05863221 | Unknown |
| Granisetron FDA approved Aug 2016 · Sustol (discontinued) |
Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 4 · NCT05434663 | Active not recruiting |
| Aprepitant FDA approved Nov 2017 · Cinvanti |
PONV | Phase 4 · NCT07639723 | Not yet recruiting |
| Tilarginine | Postoperative Pain | Phase 4 · NCT06109428 | Completed |
| Liposomal Bupivacaine | Analgesia | Phase 4 · NCT04102267 | Completed |
| Bupivacaine Hydrochloride | Analgesia | Phase 4 · NCT05109312 | Active not recruiting |
| Bupivacaine HCl without epinephrine via… | Analgesia | Phase 4 · NCT04102267 | Completed |
| APF530 | Chemotherapy-induced Nausea and Vomiting | Phase 3 · NCT02106494 | Completed |
| Fosaprepitant | Chemotherapy-induced Nausea and Vomiting | Phase 3 · NCT02106494 | Completed |
| Bupivacaine HCl without epinephrine | Postoperative Pain | Phase 2 · NCT03011333 | Completed |
| Bupivacaine HCI without epinephrine | Post-Operative Pain | Phase 2 · NCT04911062 | Completed |
| Ropivacaine | Postoperative Pain | Phase 2 · NCT03015532 | Completed |
| Bupivicaine HCl | Postoperative Pain | Phase 2 · NCT02689258 | Completed |
| Aprepitant injectable emulsion | COVID-19 | Phase 2 · NCT04470622 | Terminated |
| Ketorolac | Postoperative Pain | Phase 2 · NCT03695367 | Completed |
| F18 FBPA Injection | Solid Tumor | Phase 1/2 · NCT07691775 | Recruiting |
Also used in these trials (approved or third-party drugs, not HRTX's own candidates): Acetaminophen, Ondansetron, Ibuprofen, Dexamethasone, Palonosetron Hydrochloride, Celecoxib, Bupivacaine Hci.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
HRTX holds $23.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.5M/quarter from operations, an estimated runway of 46.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HRTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Rubric Capital Management LP | Institution (13G, 5%+) | 30,046,828 | 15.79% | 2025-10-15 |
| Clearline Capital LP | Institution (13G, 5%+) | 12,235,239 | 6.43% | 2025-12-31 |
| Adam Morgan Director |
Insider | 8,877,027 | 4.67% | 2026-01-30 |
| Craig A Collard Chief Executive Officer, Director · +1.91M options |
Insider | 931,086 | 0.49% | 2026-10-30 |
| Ira Duarte EVP, Chief Financial Officer · +538,372 options |
Insider | 302,724 | 0.16% | 2026-10-30 |
| William P Forbes EVP, Chief Development Officer · +481,878 options |
Insider | 260,734 | 0.14% | 2026-10-30 |
| Mark Earl Hensley Chief Operating Officer · +689,129 options |
Insider | 201,683 | 0.11% | 2026-11-06 |
| Craig A Johnson Director |
Insider | 53,960 | 0.03% | 2026-01-30 |
| Thomas Cusack Director · +227,272 options |
Insider | 53,960 | 0.03% | 2026-01-30 |
| Waage Christian Director |
Insider | 53,960 | 0.03% | 2026-01-30 |
| Michael Kaseta Director |
Insider | 53,960 | 0.03% | 2026-01-30 |
| Sharmila Dissanaike Director |
Insider | 53,960 | 0.03% | 2026-01-30 |
Share count 190,273,587 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HRTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →